
    
      This is a phase IB study investigating the pharmacokinetics of the combination venetoclax and
      obinutuzumab in the cerebrospinal fluid of patient with relapsed primary CNS lymphoma. Three
      dosing groups of venetoclax (600mg, 800mg, and 1000mg) are planned; dosing of obinutuzumab
      will be 1000mg for each dosing group. 15 patients are planned being included from two centers
      in Germany.
    
  